Qrons Inc. (QRON) Stock Analysis

Qrons Inc. (QRON) Healthcare & Pipeline Overview

Qrons Inc. is a biotechnology firm specializing in the development of innovative treatments for neuronal diseases, including QS100 for penetrating brain injuries and QS200 for concussions. Utilizing mesenchymal stem cells and synthetic hydrogels, Qrons operates within the competitive healthcare sector, focusing on unmet needs in neurological therapeutics.

What Is the Investment Thesis for QRON?

Qrons Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing innovative treatments for neuronal diseases, particularly brain injuries and concussions, addresses a significant unmet medical need. Key value drivers include the successful development and commercialization of QS100 and QS200. The potential market for these products is substantial, given the prevalence of brain injuries and concussions. However, the company's small size and limited resources pose significant challenges. As of 2026, Qrons has a market capitalization of $0.00 billion, indicating its early stage of development. The company's P/E ratio is 1.59, which may not be representative given its current stage. The success of Qrons hinges on its ability to secure funding, navigate regulatory hurdles, and demonstrate clinical efficacy. Upcoming catalysts include preclinical and clinical trial results for QS100 and QS200. Potential risks include clinical trial failures, regulatory setbacks, and competition from larger, more established biotechnology companies.

Based on FMP financials and quantitative analysis

QRON Key Highlights

Qrons Inc. is focused on developing treatments for neuronal diseases, including brain injuries and concussions.

• The company's lead product candidate, QS100, is a 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel for treating penetrating brain injuries.
• QS200, another key product, is an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries.
• Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York.
• The company has a small team of 10 employees, indicating its early stage of development.

Who Are QRON's Competitors?

QRON is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are QRON's Key Strengths?

Innovative stem cell and hydrogel technology.

• Focus on unmet medical needs in neurology.
• Potential for targeted and regenerative therapies.
• Proprietary product candidates (QS100 and QS200).

What Are QRON's Weaknesses?

Small size and limited resources.

• Early stage of development.
• Dependence on successful clinical trials.
• OTC market listing.

What Could Drive QRON Stock Higher?

Preclinical trial results for QS100 for penetrating brain injuries.

• Preclinical trial results for QS200 for concussions and diffused axonal injuries.
• Potential strategic partnerships with pharmaceutical companies for funding and expertise.
• Development of next-generation hydrogels with improved biocompatibility.
• Regulatory approvals for QS100 and QS200 from agencies like the FDA.

What Are the Key Risks for QRON?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures for QS100 and QS200.
• Regulatory setbacks in obtaining approvals from agencies like the FDA.
• Competition from larger biotechnology companies with more resources.
• Funding challenges and the need for additional capital.
• Limited liquidity due to OTC market listing.

What Are the Growth Opportunities for QRON?

• Expansion of QS100 into Additional Indications: Qrons has the opportunity to expand the application of QS100 beyond penetrating brain injuries to address other types of traumatic brain injuries. By demonstrating the efficacy of QS100 in a broader range of TBI cases, Qrons can significantly increase its market potential. This expansion would require additional clinical trials and regulatory approvals, with a timeline of 3-5 years.
• Development of Next-Generation Hydrogels: Qrons can invest in research and development to create next-generation hydrogels with improved biocompatibility, biodegradability, and drug delivery capabilities. The global market for hydrogels is projected to reach $15 billion by 2028. By developing advanced hydrogels, Qrons can enhance the performance of its existing products and create new therapeutic applications. This initiative would involve collaborations with material science experts and require ongoing investment in research infrastructure, with a timeline of 2-4 years.
• Strategic Partnerships with Pharmaceutical Companies: Qrons can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly seeking collaborations with smaller biotechnology companies to access innovative technologies. By forming strategic alliances, Qrons can mitigate its financial risks and expedite the path to market, with a timeline of 1-3 years.
• Geographic Expansion into International Markets: Qrons can expand its operations into international markets, particularly in Europe and Asia, where there is a growing demand for advanced neurological therapies. The global market for neurological disease treatments is expected to reach $150 billion by 2027. By establishing a presence in key international markets, Qrons can diversify its revenue streams and tap into new patient populations. This expansion would require regulatory approvals and the establishment of local partnerships, with a timeline of 3-5 years.
• Application of Technology to Other Neurological Disorders: Qrons can leverage its expertise in stem cell therapies and hydrogels to develop treatments for other neurological disorders, such as Alzheimer's disease and Parkinson's disease. The market for these disorders is substantial and growing, driven by an aging population. By expanding its therapeutic focus, Qrons can diversify its product pipeline and create new revenue opportunities. This expansion would require significant investment in research and development, with a timeline of 5-7 years.

What Are QRON's Competitive Advantages?

• Proprietary stem cell and hydrogel technology for targeted drug delivery.
• Patents protecting their innovative treatment approaches.
• First-mover advantage in developing specific therapies for brain injuries.
• Specialized expertise in regenerative medicine for neurological conditions.

What Does QRON Do?

Qrons Inc., formerly known as BioLabMart Inc., was founded in 2016 and is based in Long Island City, New York. The company is dedicated to the development of biotech products, treatments, and technologies aimed at combating neuronal diseases. Qrons' primary focus is on addressing unmet medical needs in the treatment of brain injuries and concussions through innovative approaches using stem cell technology and advanced materials. Their lead product candidates include QS100, an injury-specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel designed to treat penetrating brain injuries. This product aims to provide a targeted and regenerative solution for severe brain trauma. The second key product, QS200, is an injectable MSCs-synthetic hydrogel intended for the treatment of concussions and other diffused axonal injuries. This therapy seeks to offer a less invasive approach to mitigate the effects of concussions and promote neuronal recovery. Qrons operates within the broader biotechnology industry, concentrating its efforts on the development of novel therapies for neurological conditions. The company's strategy involves leveraging advancements in stem cell research and material science to create effective and accessible treatments for patients suffering from brain injuries and related disorders. As a relatively small company with 10 employees, Qrons is focused on advancing its product candidates through preclinical and clinical development stages, with the ultimate goal of commercializing its technologies to improve patient outcomes.

What Products and Services Does QRON Offer?

• Develops biotech products to combat neuronal diseases.
• Creates treatments for penetrating brain injuries.
• Develops therapies for concussions and diffused axonal injuries.
• Utilizes mesenchymal stem cells (MSCs) in their treatments.
• Employs synthetic hydrogels for targeted drug delivery.
• Focuses on regenerative medicine approaches for neurological conditions.
• Aims to provide innovative solutions for unmet medical needs in neurology.

How Does QRON Make Money?

• Develops and patents novel therapeutic technologies.
• Conducts preclinical and clinical trials to demonstrate efficacy and safety.
• Seeks regulatory approvals from agencies like the FDA.
• Potentially partners with larger pharmaceutical companies for commercialization or out-licensing.

What Industry Does QRON Operate In?

Qrons Inc. operates within the biotechnology industry, which is characterized by high levels of innovation, intense competition, and significant regulatory oversight. The market for neurological disease treatments is substantial and growing, driven by an aging population, increased awareness of brain injuries, and advancements in diagnostic technologies. Qrons competes with other biotechnology and pharmaceutical companies developing therapies for brain injuries and concussions. The competitive landscape includes both established players with extensive resources and smaller, emerging companies focused on niche markets. Key trends in the industry include the increasing use of stem cell therapies, the development of advanced drug delivery systems, and the growing importance of personalized medicine.

Who Are QRON's Key Customers?

• Hospitals and medical centers specializing in neurology and neurosurgery.
• Patients suffering from brain injuries, concussions, and other neuronal diseases.
• Rehabilitation centers focused on treating patients with neurological disorders.
• Potentially, military and sports organizations dealing with brain trauma.

Company Profile

Qrons Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Glendale, US. The company is led by CEO Cory J. Rosenberg. QRON has traded publicly since 2021.

Qrons Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for Qrons Inc. stands at 5.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -30.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -36.4%, the inverse of the P/E and a quick read on earnings relative to price.

Quarterly Financial Performance: Qrons Inc.

Revenue for Qrons Inc. came in at $0 during Q4 2024. The company recorded net income of $159K, with diluted EPS of $0.01. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, QRON averaged $-0.00 in diluted EPS.

The most recent 12 insider filings for Qrons Inc. break down as 2 sales and 10 purchases. On net that is roughly 3.1M shares acquired (about $6.3M) — insiders putting money in tends to read as conviction.

QRON Financials

QRON Latest News

No recent news available for QRON.

QRON Analyst Consensus

QRON MoonshotScore

Common Questions About QRON (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources